I heard that slipup too. In a latter broadcast on PBS in mid Jan. 2011 ( this broadcast was from late 2010 ) she had her facts straight. Note that the video we just watched was made before they had signed up the Japanese firm with the $227 million upfront and milestone payments and before the secondary offering with the $77 million sale price. That's $304 million more cash and promised cash (milestone payments) than they had before she made her recommendation and set her price target. The stock price has overcome more than half of the dilution since Feb. 16th, indicating to me that there are a lot of believers out there that this company will get FDA approval.
I would suggest that a takeover price of $22-$25 is possible.